制吐剤の世界市場 2023-2027

制吐剤市場は2022-2027年に16億3,281万米ドル、予測期間中のCAGRは6.47％で成長すると予測されます。

当レポートでは、制吐剤市場の全体的な分析、市場規模・予測、動向、市場促進要因・促進要因、課題、約25のベンダーを網羅したベンダー分析などを掲載しています。

現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。市場は、世界の高齢人口の増加、吐き気・嘔吐の有病率の増加、ヘルスケア支出の増加が牽引しています。

本調査では、制吐剤管理におけるデジタルヘルスソリューションの統合が、今後数年間の制吐剤市場成長を促進する主要な理由の1つであると特定しています。また、制吐剤に関連する最近の開発件数の増加や新興経済における制吐剤需要の高まりも、市場の大きな需要につながるでしょう。

目次

第1章 エグゼクティブサマリー

• 市場概要

第2章 市場情勢

• 市場エコシステム

第3章 市場規模

• 市場の定義
• 市場セグメント分析
• 市場規模 2022
• 市場の見通し 2022-2027

第4章 市場規模実績

• 制吐剤の世界市場 2017-2021
• 薬剤クラス別セグメント分析 2017-2021
• 用途別セグメント分析 2017-2021
• 地域別セグメント分析 2017-2021
• 国別セグメント分析 2017-2021

第5章 ファイブフォース分析

• ファイブフォースの要約
• 買い手の交渉力
• 供給企業の交渉力
• 新規参入業者の脅威
• 代替品の脅威
• 競争の脅威
• 市況

第6章 市場セグメンテーション：薬剤クラス別

• 市場セグメント
• 比較：薬剤クラス別
• 5-ヒドロキシトリプタミン3（5-HT 3）受容体拮抗薬：市場規模と予測 2022-2027
• ドーパミン拮抗薬：市場規模と予測 2022-2027
• ニューロキニン-1（NK 1）受容体拮抗薬：市場規模と予測 2022-2027
• カンナビノイド受容体拮抗薬：市場規模と予測 2022-2027
• その他：市場規模と予測 2022-2027
• 市場機会：薬剤クラス別

第7章 市場セグメンテーション：用途別

• 市場セグメント
• 比較：用途別
• 化学療法：市場規模と予測 2022-2027
• 手術：市場規模と予測 2022-2027
• 胃腸炎：市場規模と予測 2022-2027
• その他：市場規模と予測 2022-2027
• 市場機会：用途別

第8章 顧客情勢

• 顧客情勢の概要

第9章 地域別情勢

• 地域別セグメンテーション
• 地域別比較
• 北米：市場規模と予測 2022-2027
• 欧州：市場規模と予測 2022-2027
• アジア：市場規模と予測 2022-2027
• 世界のその他の地域：市場規模と予測 2022-2027
• 米国：市場規模と予測 2022-2027
• 中国：市場規模と予測 2022-2027
• ドイツ：市場規模と予測 2022-2027
• 日本：市場規模と予測 2022-2027
• 英国：市場規模と予測 2022-2027
• 市場機会：地域情勢別

第10章 促進要因、課題、および動向

• 市場促進要因
• 市場の課題
• 促進要因と課題の影響
• 市場動向

第11章 ベンダー情勢

• 概要
• ベンダー情勢
• 混乱の状況
• 業界のリスク

第12章 ベンダー分析

• 対象ベンダー
• ベンダーの市場ポジショニング
• Boehringer Ingelheim International GmbH
• Cadila Pharmaceuticals Ltd.
• Cipla Ltd.
• Fresenius SE and Co. KGaA
• GlaxoSmithKline Plc
• Helsinn Healthcare SA
• Lupin Ltd.
• Merck and Co. Inc.
• Novartis AG
• Otsuka Holdings Co. Ltd.
• Pfizer Inc.
• Sanofi
• Takeda Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.

第13章 付録

Exhibits:

• Exhibits1: Executive Summary - Chart on Market Overview
• Exhibits2: Executive Summary - Data Table on Market Overview
• Exhibits3: Executive Summary - Chart on Global Market Characteristics
• Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
• Exhibits5: Executive Summary - Chart on Market Segmentation by Drug Class
• Exhibits6: Executive Summary - Chart on Market Segmentation by Application
• Exhibits7: Executive Summary - Chart on Incremental Growth
• Exhibits8: Executive Summary - Data Table on Incremental Growth
• Exhibits9: Executive Summary - Chart on Vendor Market Positioning
• Exhibits10: Parent market
• Exhibits11: Market Characteristics
• Exhibits12: Offerings of vendors included in the market definition
• Exhibits13: Market segments
• Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibits18: Historic Market Size - Data Table on global antiemetic drug market 2017 - 2021 ($ million)
• Exhibits19: Historic Market Size - Drug Class Segment 2017 - 2021 ($ million)
• Exhibits20: Historic Market Size - Application Segment 2017 - 2021 ($ million)
• Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
• Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
• Exhibits23: Five forces analysis - Comparison between 2022 and 2027
• Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
• Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
• Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027
• Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027
• Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027
• Exhibits29: Chart on Market condition - Five forces 2022 and 2027
• Exhibits30: Chart on Drug Class - Market share 2022-2027 (%)
• Exhibits31: Data Table on Drug Class - Market share 2022-2027 (%)
• Exhibits32: Chart on Comparison by Drug Class
• Exhibits33: Data Table on Comparison by Drug Class
• Exhibits34: Chart on 5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist - Market size and forecast 2022-2027 ($ million)
• Exhibits35: Data Table on 5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist - Market size and forecast 2022-2027 ($ million)
• Exhibits36: Chart on 5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist - Year-over-year growth 2022-2027 (%)
• Exhibits37: Data Table on 5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist - Year-over-year growth 2022-2027 (%)
• Exhibits38: Chart on Dopamine antagonist - Market size and forecast 2022-2027 ($ million)
• Exhibits39: Data Table on Dopamine antagonist - Market size and forecast 2022-2027 ($ million)
• Exhibits40: Chart on Dopamine antagonist - Year-over-year growth 2022-2027 (%)
• Exhibits41: Data Table on Dopamine antagonist - Year-over-year growth 2022-2027 (%)
• Exhibits42: Chart on Neurokinin-1 (NK 1) receptor antagonist - Market size and forecast 2022-2027 ($ million)
• Exhibits43: Data Table on Neurokinin-1 (NK 1) receptor antagonist - Market size and forecast 2022-2027 ($ million)
• Exhibits44: Chart on Neurokinin-1 (NK 1) receptor antagonist - Year-over-year growth 2022-2027 (%)
• Exhibits45: Data Table on Neurokinin-1 (NK 1) receptor antagonist - Year-over-year growth 2022-2027 (%)
• Exhibits46: Chart on Cannabinoid receptor antagonist - Market size and forecast 2022-2027 ($ million)
• Exhibits47: Data Table on Cannabinoid receptor antagonist - Market size and forecast 2022-2027 ($ million)
• Exhibits48: Chart on Cannabinoid receptor antagonist - Year-over-year growth 2022-2027 (%)
• Exhibits49: Data Table on Cannabinoid receptor antagonist - Year-over-year growth 2022-2027 (%)
• Exhibits50: Chart on Others - Market size and forecast 2022-2027 ($ million)
• Exhibits51: Data Table on Others - Market size and forecast 2022-2027 ($ million)
• Exhibits52: Chart on Others - Year-over-year growth 2022-2027 (%)
• Exhibits53: Data Table on Others - Year-over-year growth 2022-2027 (%)
• Exhibits54: Market opportunity by Drug Class ($ million)
• Exhibits55: Data Table on Market opportunity by Drug Class ($ million)
• Exhibits56: Chart on Application - Market share 2022-2027 (%)
• Exhibits57: Data Table on Application - Market share 2022-2027 (%)
• Exhibits58: Chart on Comparison by Application
• Exhibits59: Data Table on Comparison by Application
• Exhibits60: Chart on Chemotherapy - Market size and forecast 2022-2027 ($ million)
• Exhibits61: Data Table on Chemotherapy - Market size and forecast 2022-2027 ($ million)
• Exhibits62: Chart on Chemotherapy - Year-over-year growth 2022-2027 (%)
• Exhibits63: Data Table on Chemotherapy - Year-over-year growth 2022-2027 (%)
• Exhibits64: Chart on Surgery - Market size and forecast 2022-2027 ($ million)
• Exhibits65: Data Table on Surgery - Market size and forecast 2022-2027 ($ million)
• Exhibits66: Chart on Surgery - Year-over-year growth 2022-2027 (%)
• Exhibits67: Data Table on Surgery - Year-over-year growth 2022-2027 (%)
• Exhibits68: Chart on Gastroenteritis - Market size and forecast 2022-2027 ($ million)
• Exhibits69: Data Table on Gastroenteritis - Market size and forecast 2022-2027 ($ million)
• Exhibits70: Chart on Gastroenteritis - Year-over-year growth 2022-2027 (%)
• Exhibits71: Data Table on Gastroenteritis - Year-over-year growth 2022-2027 (%)
• Exhibits72: Chart on Others - Market size and forecast 2022-2027 ($ million)
• Exhibits73: Data Table on Others - Market size and forecast 2022-2027 ($ million)
• Exhibits74: Chart on Others - Year-over-year growth 2022-2027 (%)
• Exhibits75: Data Table on Others - Year-over-year growth 2022-2027 (%)
• Exhibits76: Market opportunity by Application ($ million)
• Exhibits77: Data Table on Market opportunity by Application ($ million)
• Exhibits78: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• Exhibits79: Chart on Market share By Geographical Landscape 2022-2027 (%)
• Exhibits80: Data Table on Market share By Geographical Landscape 2022-2027 (%)
• Exhibits81: Chart on Geographic comparison
• Exhibits82: Data Table on Geographic comparison
• Exhibits83: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibits84: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibits85: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibits86: Data Table on North America - Year-over-year growth 2022-2027 (%)
• Exhibits87: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibits88: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibits89: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibits90: Data Table on Europe - Year-over-year growth 2022-2027 (%)
• Exhibits91: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibits92: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibits93: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibits94: Data Table on Asia - Year-over-year growth 2022-2027 (%)
• Exhibits95: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibits96: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibits97: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibits98: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibits99: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibits100: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibits101: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibits102: Data Table on US - Year-over-year growth 2022-2027 (%)
• Exhibits103: Chart on China - Market size and forecast 2022-2027 ($ million)
• Exhibits104: Data Table on China - Market size and forecast 2022-2027 ($ million)
• Exhibits105: Chart on China - Year-over-year growth 2022-2027 (%)
• Exhibits106: Data Table on China - Year-over-year growth 2022-2027 (%)
• Exhibits107: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibits108: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibits109: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibits110: Data Table on Germany - Year-over-year growth 2022-2027 (%)
• Exhibits111: Chart on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibits112: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibits113: Chart on Japan - Year-over-year growth 2022-2027 (%)
• Exhibits114: Data Table on Japan - Year-over-year growth 2022-2027 (%)
• Exhibits115: Chart on UK - Market size and forecast 2022-2027 ($ million)
• Exhibits116: Data Table on UK - Market size and forecast 2022-2027 ($ million)
• Exhibits117: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibits118: Data Table on UK - Year-over-year growth 2022-2027 (%)
• Exhibits119: Market opportunity By Geographical Landscape ($ million)
• Exhibits120: Data Tables on Market opportunity By Geographical Landscape ($ million)
• Exhibits121: Impact of drivers and challenges in 2022 and 2027
• Exhibits122: Overview on Criticality of inputs and Factors of differentiation
• Exhibits123: Overview on factors of disruption
• Exhibits124: Impact of key risks on business
• Exhibits125: Vendors covered
• Exhibits126: Matrix on vendor position and classification
• Exhibits127: Boehringer Ingelheim International GmbH - Overview
• Exhibits128: Boehringer Ingelheim International GmbH - Business segments
• Exhibits129: Boehringer Ingelheim International GmbH - Key news
• Exhibits130: Boehringer Ingelheim International GmbH - Key offerings
• Exhibits131: Boehringer Ingelheim International GmbH - Segment focus
• Exhibits132: Cadila Pharmaceuticals Ltd. - Overview
• Exhibits133: Cadila Pharmaceuticals Ltd. - Product / Service
• Exhibits134: Cadila Pharmaceuticals Ltd. - Key offerings
• Exhibits135: Cipla Ltd. - Overview
• Exhibits136: Cipla Ltd. - Business segments
• Exhibits137: Cipla Ltd. - Key news
• Exhibits138: Cipla Ltd. - Key offerings
• Exhibits139: Cipla Ltd. - Segment focus
• Exhibits140: Fresenius SE and Co. KGaA - Overview
• Exhibits141: Fresenius SE and Co. KGaA - Business segments
• Exhibits142: Fresenius SE and Co. KGaA - Key news
• Exhibits143: Fresenius SE and Co. KGaA - Key offerings
• Exhibits144: Fresenius SE and Co. KGaA - Segment focus
• Exhibits145: GlaxoSmithKline Plc - Overview
• Exhibits146: GlaxoSmithKline Plc - Business segments
• Exhibits147: GlaxoSmithKline Plc - Key news
• Exhibits148: GlaxoSmithKline Plc - Key offerings
• Exhibits149: GlaxoSmithKline Plc - Segment focus
• Exhibits150: Helsinn Healthcare SA - Overview
• Exhibits151: Helsinn Healthcare SA - Product / Service
• Exhibits152: Helsinn Healthcare SA - Key offerings
• Exhibits153: Lupin Ltd. - Overview
• Exhibits154: Lupin Ltd. - Product / Service
• Exhibits155: Lupin Ltd. - Key news
• Exhibits156: Lupin Ltd. - Key offerings
• Exhibits157: Merck and Co. Inc. - Overview
• Exhibits158: Merck and Co. Inc. - Business segments
• Exhibits159: Merck and Co. Inc. - Key news
• Exhibits160: Merck and Co. Inc. - Key offerings
• Exhibits161: Merck and Co. Inc. - Segment focus
• Exhibits162: Novartis AG - Overview
• Exhibits163: Novartis AG - Business segments
• Exhibits164: Novartis AG - Key offerings
• Exhibits165: Novartis AG - Segment focus
• Exhibits166: Otsuka Holdings Co. Ltd. - Overview
• Exhibits167: Otsuka Holdings Co. Ltd. - Business segments
• Exhibits168: Otsuka Holdings Co. Ltd. - Key offerings
• Exhibits169: Otsuka Holdings Co. Ltd. - Segment focus
• Exhibits170: Pfizer Inc. - Overview
• Exhibits171: Pfizer Inc. - Product / Service
• Exhibits172: Pfizer Inc. - Key news
• Exhibits173: Pfizer Inc. - Key offerings
• Exhibits174: Sanofi - Overview
• Exhibits175: Sanofi - Business segments
• Exhibits176: Sanofi - Key news
• Exhibits177: Sanofi - Key offerings
• Exhibits178: Sanofi - Segment focus
• Exhibits179: Takeda Pharmaceutical Co. Ltd. - Overview
• Exhibits180: Takeda Pharmaceutical Co. Ltd. - Product / Service
• Exhibits181: Takeda Pharmaceutical Co. Ltd. - Key news
• Exhibits182: Takeda Pharmaceutical Co. Ltd. - Key offerings
• Exhibits183: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibits184: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibits185: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibits186: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibits187: Teva Pharmaceutical Industries Ltd. - Segment focus
• Exhibits188: Viatris Inc. - Overview
• Exhibits189: Viatris Inc. - Business segments
• Exhibits190: Viatris Inc. - Key news
• Exhibits191: Viatris Inc. - Key offerings
• Exhibits192: Viatris Inc. - Segment focus
• Exhibits193: Inclusions checklist
• Exhibits194: Exclusions checklist
• Exhibits195: Currency conversion rates for US$
• Exhibits196: Research methodology
• Exhibits197: Validation techniques employed for market sizing
• Exhibits198: Information sources
• Exhibits199: List of abbreviations

The antiemetic drug market is forecasted to grow by USD 1,632.81 mn during 2022-2027, accelerating at a CAGR of 6.47% during the forecast period. The report on the antiemetic drug market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising geriatric population globally, growing prevalence of nausea and vomiting, and increasing healthcare expenditure.

Technavio's antiemetic drug market is segmented as below:

By Application

• Chemotherapy
• Surgery
• Gastroenteritis
• Others

By Drug Class

• 5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist
• Dopamine antagonist
• Neurokinin-1 (NK 1) receptor antagonist
• Cannabinoid receptor antagonist
• Others

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the integration of digital health solutions in antiemetic drug management as one of the prime reasons driving the antiemetic drug market growth during the next few years. Also, growing number of recent developments related to antiemetic drugs and rising demand for antiemetic drugs in emerging economies will lead to sizable demand in the market.

The report on the antiemetic drug market covers the following areas:

• Antiemetic drug market sizing
• Antiemetic drug market forecast
• Antiemetic drug market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading antiemetic drug market vendors that include Algen Healthcare Ltd., Boehringer Ingelheim International GmbH, Bristol Laboratories Ltd., Cadila Pharmaceuticals Ltd., Cipla Ltd., Eagle Pharmaceuticals Inc., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, Helsinn Healthcare SA, Heron Therapeutics Inc., Lupin Ltd., Merck and Co. Inc., Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., RedHill Biopharma Ltd., Sanofi, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc.. Also, the antiemetic drug market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary - Chart on Market Overview
• Exhibit 02: Executive Summary - Data Table on Market Overview
• Exhibit 03: Executive Summary - Chart on Global Market Characteristics
• Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
• Exhibit 05: Executive Summary - Chart on Market Segmentation by Drug Class
• Exhibit 06: Executive Summary - Chart on Market Segmentation by Application
• Exhibit 07: Executive Summary - Chart on Incremental Growth
• Exhibit 08: Executive Summary - Data Table on Incremental Growth
• Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition
• 3.2 Market segment analysis
• Exhibit 13: Market segments
• 3.3 Market size 2022
• 3.4 Market outlook: Forecast for 2022-2027
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global antiemetic drug market 2017 - 2021
• Exhibit 18: Historic Market Size - Data Table on global antiemetic drug market 2017 - 2021 ($ million)
• 4.2 Drug Class Segment Analysis 2017 - 2021
• Exhibit 19: Historic Market Size - Drug Class Segment 2017 - 2021 ($ million)
• 4.3 Application Segment Analysis 2017 - 2021
• Exhibit 20: Historic Market Size - Application Segment 2017 - 2021 ($ million)
• 4.4 Geography Segment Analysis 2017 - 2021
• Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
• 4.5 Country Segment Analysis 2017 - 2021
• Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
• 5.2 Bargaining power of buyers
• Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
• 5.3 Bargaining power of suppliers
• Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
• 5.4 Threat of new entrants
• Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
• 5.5 Threat of substitutes
• Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Drug Class

• 6.1 Market segments
• Exhibit 30: Chart on Drug Class - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Drug Class - Market share 2022-2027 (%)
• 6.2 Comparison by Drug Class
• Exhibit 32: Chart on Comparison by Drug Class
• Exhibit 33: Data Table on Comparison by Drug Class
• 6.3 5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist - Market size and forecast 2022-2027
• Exhibit 34: Chart on 5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist - Market size and forecast 2022-2027 ($ million)
• Exhibit 35: Data Table on 5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist - Market size and forecast 2022-2027 ($ million)
• Exhibit 36: Chart on 5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on 5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist - Year-over-year growth 2022-2027 (%)
• 6.4 Dopamine antagonist - Market size and forecast 2022-2027
• Exhibit 38: Chart on Dopamine antagonist - Market size and forecast 2022-2027 ($ million)
• Exhibit 39: Data Table on Dopamine antagonist - Market size and forecast 2022-2027 ($ million)
• Exhibit 40: Chart on Dopamine antagonist - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Dopamine antagonist - Year-over-year growth 2022-2027 (%)
• 6.5 Neurokinin-1 (NK 1) receptor antagonist - Market size and forecast 2022-2027
• Exhibit 42: Chart on Neurokinin-1 (NK 1) receptor antagonist - Market size and forecast 2022-2027 ($ million)
• Exhibit 43: Data Table on Neurokinin-1 (NK 1) receptor antagonist - Market size and forecast 2022-2027 ($ million)
• Exhibit 44: Chart on Neurokinin-1 (NK 1) receptor antagonist - Year-over-year growth 2022-2027 (%)
• Exhibit 45: Data Table on Neurokinin-1 (NK 1) receptor antagonist - Year-over-year growth 2022-2027 (%)
• 6.6 Cannabinoid receptor antagonist - Market size and forecast 2022-2027
• Exhibit 46: Chart on Cannabinoid receptor antagonist - Market size and forecast 2022-2027 ($ million)
• Exhibit 47: Data Table on Cannabinoid receptor antagonist - Market size and forecast 2022-2027 ($ million)
• Exhibit 48: Chart on Cannabinoid receptor antagonist - Year-over-year growth 2022-2027 (%)
• Exhibit 49: Data Table on Cannabinoid receptor antagonist - Year-over-year growth 2022-2027 (%)
• 6.7 Others - Market size and forecast 2022-2027
• Exhibit 50: Chart on Others - Market size and forecast 2022-2027 ($ million)
• Exhibit 51: Data Table on Others - Market size and forecast 2022-2027 ($ million)
• Exhibit 52: Chart on Others - Year-over-year growth 2022-2027 (%)
• Exhibit 53: Data Table on Others - Year-over-year growth 2022-2027 (%)
• 6.8 Market opportunity by Drug Class
• Exhibit 54: Market opportunity by Drug Class ($ million)
• Exhibit 55: Data Table on Market opportunity by Drug Class ($ million)

7 Market Segmentation by Application

• 7.1 Market segments
• Exhibit 56: Chart on Application - Market share 2022-2027 (%)
• Exhibit 57: Data Table on Application - Market share 2022-2027 (%)
• 7.2 Comparison by Application
• Exhibit 58: Chart on Comparison by Application
• Exhibit 59: Data Table on Comparison by Application
• 7.3 Chemotherapy - Market size and forecast 2022-2027
• Exhibit 60: Chart on Chemotherapy - Market size and forecast 2022-2027 ($ million)
• Exhibit 61: Data Table on Chemotherapy - Market size and forecast 2022-2027 ($ million)
• Exhibit 62: Chart on Chemotherapy - Year-over-year growth 2022-2027 (%)
• Exhibit 63: Data Table on Chemotherapy - Year-over-year growth 2022-2027 (%)
• 7.4 Surgery - Market size and forecast 2022-2027
• Exhibit 64: Chart on Surgery - Market size and forecast 2022-2027 ($ million)
• Exhibit 65: Data Table on Surgery - Market size and forecast 2022-2027 ($ million)
• Exhibit 66: Chart on Surgery - Year-over-year growth 2022-2027 (%)
• Exhibit 67: Data Table on Surgery - Year-over-year growth 2022-2027 (%)
• 7.5 Gastroenteritis - Market size and forecast 2022-2027
• Exhibit 68: Chart on Gastroenteritis - Market size and forecast 2022-2027 ($ million)
• Exhibit 69: Data Table on Gastroenteritis - Market size and forecast 2022-2027 ($ million)
• Exhibit 70: Chart on Gastroenteritis - Year-over-year growth 2022-2027 (%)
• Exhibit 71: Data Table on Gastroenteritis - Year-over-year growth 2022-2027 (%)
• 7.6 Others - Market size and forecast 2022-2027
• Exhibit 72: Chart on Others - Market size and forecast 2022-2027 ($ million)
• Exhibit 73: Data Table on Others - Market size and forecast 2022-2027 ($ million)
• Exhibit 74: Chart on Others - Year-over-year growth 2022-2027 (%)
• Exhibit 75: Data Table on Others - Year-over-year growth 2022-2027 (%)
• 7.7 Market opportunity by Application
• Exhibit 76: Market opportunity by Application ($ million)
• Exhibit 77: Data Table on Market opportunity by Application ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview
• Exhibit 78: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
• Exhibit 79: Chart on Market share By Geographical Landscape 2022-2027 (%)
• Exhibit 80: Data Table on Market share By Geographical Landscape 2022-2027 (%)
• 9.2 Geographic comparison
• Exhibit 81: Chart on Geographic comparison
• Exhibit 82: Data Table on Geographic comparison
• 9.3 North America - Market size and forecast 2022-2027
• Exhibit 83: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 84: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 85: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 86: Data Table on North America - Year-over-year growth 2022-2027 (%)
• 9.4 Europe - Market size and forecast 2022-2027
• Exhibit 87: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 88: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 89: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 90: Data Table on Europe - Year-over-year growth 2022-2027 (%)
• 9.5 Asia - Market size and forecast 2022-2027
• Exhibit 91: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 92: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 93: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 94: Data Table on Asia - Year-over-year growth 2022-2027 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
• Exhibit 95: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 96: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 97: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 98: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• 9.7 US - Market size and forecast 2022-2027
• Exhibit 99: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 100: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 101: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 102: Data Table on US - Year-over-year growth 2022-2027 (%)
• 9.8 China - Market size and forecast 2022-2027
• Exhibit 103: Chart on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 104: Data Table on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 105: Chart on China - Year-over-year growth 2022-2027 (%)
• Exhibit 106: Data Table on China - Year-over-year growth 2022-2027 (%)
• 9.9 Germany - Market size and forecast 2022-2027
• Exhibit 107: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 108: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 109: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibit 110: Data Table on Germany - Year-over-year growth 2022-2027 (%)
• 9.10 Japan - Market size and forecast 2022-2027
• Exhibit 111: Chart on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibit 112: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibit 113: Chart on Japan - Year-over-year growth 2022-2027 (%)
• Exhibit 114: Data Table on Japan - Year-over-year growth 2022-2027 (%)
• 9.11 UK - Market size and forecast 2022-2027
• Exhibit 115: Chart on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 116: Data Table on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 117: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibit 118: Data Table on UK - Year-over-year growth 2022-2027 (%)
• 9.12 Market opportunity By Geographical Landscape
• Exhibit 119: Market opportunity By Geographical Landscape ($ million)
• Exhibit 120: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• Exhibit 121: Impact of drivers and challenges in 2022 and 2027
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• Exhibit 122: Overview on Criticality of inputs and Factors of differentiation
• 11.3 Landscape disruption
• Exhibit 123: Overview on factors of disruption
• 11.4 Industry risks
• Exhibit 124: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 125: Vendors covered
• 12.2 Market positioning of vendors
• Exhibit 126: Matrix on vendor position and classification
• 12.3 Boehringer Ingelheim International GmbH
• Exhibit 127: Boehringer Ingelheim International GmbH - Overview
• Exhibit 128: Boehringer Ingelheim International GmbH - Business segments
• Exhibit 129: Boehringer Ingelheim International GmbH - Key news
• Exhibit 130: Boehringer Ingelheim International GmbH - Key offerings
• Exhibit 131: Boehringer Ingelheim International GmbH - Segment focus
• 12.4 Cadila Pharmaceuticals Ltd.
• Exhibit 132: Cadila Pharmaceuticals Ltd. - Overview
• Exhibit 133: Cadila Pharmaceuticals Ltd. - Product / Service
• Exhibit 134: Cadila Pharmaceuticals Ltd. - Key offerings
• 12.5 Cipla Ltd.
• Exhibit 135: Cipla Ltd. - Overview
• Exhibit 136: Cipla Ltd. - Business segments
• Exhibit 137: Cipla Ltd. - Key news
• Exhibit 138: Cipla Ltd. - Key offerings
• Exhibit 139: Cipla Ltd. - Segment focus
• 12.6 Fresenius SE and Co. KGaA
• Exhibit 140: Fresenius SE and Co. KGaA - Overview
• Exhibit 141: Fresenius SE and Co. KGaA - Business segments
• Exhibit 142: Fresenius SE and Co. KGaA - Key news
• Exhibit 143: Fresenius SE and Co. KGaA - Key offerings
• Exhibit 144: Fresenius SE and Co. KGaA - Segment focus
• 12.7 GlaxoSmithKline Plc
• Exhibit 145: GlaxoSmithKline Plc - Overview
• Exhibit 146: GlaxoSmithKline Plc - Business segments
• Exhibit 147: GlaxoSmithKline Plc - Key news
• Exhibit 148: GlaxoSmithKline Plc - Key offerings
• Exhibit 149: GlaxoSmithKline Plc - Segment focus
• 12.8 Helsinn Healthcare SA
• Exhibit 150: Helsinn Healthcare SA - Overview
• Exhibit 151: Helsinn Healthcare SA - Product / Service
• Exhibit 152: Helsinn Healthcare SA - Key offerings
• 12.9 Lupin Ltd.
• Exhibit 153: Lupin Ltd. - Overview
• Exhibit 154: Lupin Ltd. - Product / Service
• Exhibit 155: Lupin Ltd. - Key news
• Exhibit 156: Lupin Ltd. - Key offerings
• 12.10 Merck and Co. Inc.
• Exhibit 157: Merck and Co. Inc. - Overview
• Exhibit 158: Merck and Co. Inc. - Business segments
• Exhibit 159: Merck and Co. Inc. - Key news
• Exhibit 160: Merck and Co. Inc. - Key offerings
• Exhibit 161: Merck and Co. Inc. - Segment focus
• 12.11 Novartis AG
• Exhibit 162: Novartis AG - Overview
• Exhibit 163: Novartis AG - Business segments
• Exhibit 164: Novartis AG - Key offerings
• Exhibit 165: Novartis AG - Segment focus
• 12.12 Otsuka Holdings Co. Ltd.
• Exhibit 166: Otsuka Holdings Co. Ltd. - Overview
• Exhibit 167: Otsuka Holdings Co. Ltd. - Business segments
• Exhibit 168: Otsuka Holdings Co. Ltd. - Key offerings
• Exhibit 169: Otsuka Holdings Co. Ltd. - Segment focus
• 12.13 Pfizer Inc.
• Exhibit 170: Pfizer Inc. - Overview
• Exhibit 171: Pfizer Inc. - Product / Service
• Exhibit 172: Pfizer Inc. - Key news
• Exhibit 173: Pfizer Inc. - Key offerings
• 12.14 Sanofi
• Exhibit 174: Sanofi - Overview
• Exhibit 175: Sanofi - Business segments
• Exhibit 176: Sanofi - Key news
• Exhibit 177: Sanofi - Key offerings
• Exhibit 178: Sanofi - Segment focus
• 12.15 Takeda Pharmaceutical Co. Ltd.
• Exhibit 179: Takeda Pharmaceutical Co. Ltd. - Overview
• Exhibit 180: Takeda Pharmaceutical Co. Ltd. - Product / Service
• Exhibit 181: Takeda Pharmaceutical Co. Ltd. - Key news
• Exhibit 182: Takeda Pharmaceutical Co. Ltd. - Key offerings
• 12.16 Teva Pharmaceutical Industries Ltd.
• Exhibit 183: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 184: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 185: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 186: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 187: Teva Pharmaceutical Industries Ltd. - Segment focus
• 12.17 Viatris Inc.
• Exhibit 188: Viatris Inc. - Overview
• Exhibit 189: Viatris Inc. - Business segments
• Exhibit 190: Viatris Inc. - Key news
• Exhibit 191: Viatris Inc. - Key offerings
• Exhibit 192: Viatris Inc. - Segment focus

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• Exhibit 193: Inclusions checklist
• Exhibit 194: Exclusions checklist
• 13.3 Currency conversion rates for US$
• Exhibit 195: Currency conversion rates for US$
• 13.4 Research methodology
• Exhibit 196: Research methodology
• Exhibit 197: Validation techniques employed for market sizing
• Exhibit 198: Information sources
• 13.5 List of abbreviations
• Exhibit 199: List of abbreviations